References
- Schafer AI. Bleeding and thrombosis in the myeloproliferative disorders. Blood 1984; 64: 1–12
- Wehmeier A, Sudhoff T, Meierkord F. Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders. Semin Thromb Hemost 1997; 23: 391–402
- Spaet TH, Gaynor E, Goldstein ML. Defective platelets in essential thrombocythemia. Arch Intern Med 1969; 124: 135–141
- Murphy S, Davis JL, Walsh PN, Gardner FH. Template bleeding time and clinical hemorrhage in myeloproliferative disease. Arch Intern Med 1978; 138: 1251–1253
- Wu KK. Platelet hyperaggregability and thrombosis in patients with thrombocythemia. Ann Intern Med 1978; 88: 7–11
- Balduini CL, Bertolino G, Noris P, Piletta GC. Platelet aggregation in platelet-rich plasma and whole blood in 120 patients with myeloproliferative disorders. Am J Clin Pathol 1991; 95: 82–86
- Mayordomo O, Carcamo C, Vecino AM, Navarro JL, Cesar JM. Arachidonic acid metabolism in platelets of patients with essential thrombocythaemia. Thromb Res 1995; 78: 315–321
- Irvine RF. How is the level of free arachidonic acid controlled in mammalian cells?. Biochem J 1982; 204: 3–16
- Bills TK, Smith JB, Silver MJ. Selective release of arachidonic acid from the phospholipids of human platelets in response to thrombin. J Clin Invest 1977; 60: 1–6
- Broekman MJ. Stimulated platelets release equivalent amounts of arachidonate from phosphatidylcholine, phosphatidylethanolamine and inositides. J Lipid Res 1986; 27: 884–891
- Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: A final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997; 34: 29–39
- Ana M Vecino, Jose L Teruel, Jose L Navarro, Jesus M Cesar. Phospholipase A2 activity in platelets of patients with uremia. Platelets 2002; 13: 415–418
- Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37: 911–917
- Cesar JM, Navarro JL. Arachidonic acid metabolism in platelets stored for 5 days. Br J Haematol 1990; 74: 294–295
- Simon IL, Martin TJ. Platelet thromboxane synthesis and release reaction in myeloproliferative disorders. Haemostasis 1982; 11: 119–127
- Rocca B, Ciabattoni G, Trataglione R, Cortelazzo S, Barbui T, Patrono C, Landolfi R. Increased thromboxane biosynthesis in essential thrombocythemia. Thromb Haemost 1995; 74: 1225–1230
- Rittenhouse-Simmons SE. Activation of human platelet phospholipase C by ionophore A23187 is totally dependant upon cyclooxygenase products and ADP. Biochem J 1984; 222: 103–110
- Borsch HAG, Bartoli F, Asselin J, Dudler T, Kramer RM, Apitz-Castro R, Watson SP, Gelb MH. Identification of the phosphorylation sites of cytosolic phospholipase A2 in agonist-stimulated human platelets and HeLa cells. J Biol Chem 1998; 273: 4449–4458
- Cesar JM, Vecino AM, Perez-Vaquero M, Navarro JL. Phospholipids determination in platelets, plasma and red cells of patients with myeloproliferative diseases. Eur J Haemat 1993; 50: 234–236
- Nugteren DH. Arachidonate lipoxygenase in blood platelets. Biochim Biophys Acta 1975; 380: 299–307
- Hamberg M, Svensson J, Samuelsson B. Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Prod Natl Acad Sci USA 1975; 72: 2994–2998
- Vane JR. The node of action of aspirin-like drugs. Agents Actions 1978; 8: 430–431